Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONCY $1.00 0.1800 +21.95%
ZIOP $3.32 0.2600 +8.50%
SRNE $4.22 0.2400 +6.03%
AEZS $1.12 0.0600 +5.66%
ONTX $4.86 0.2100 +4.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BIND $8.05 -0.8900 -9.96%
GALE $2.05 -0.1600 -7.24%
ARRY $3.59 -0.2800 -7.24%
APRI $1.48 -0.1000 -6.33%
ONTY $1.80 -0.1200 -6.25%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Key Research From Inaugural 2014 Palliative Care in Oncology Symposium Highlights Advances in Integrating Palliative Care into Treatment and Financial Hardships Facing People Living with Cancer

(ASCO) Oct 21, 2014 - Four studies highlighted in an embargoed presscast yesterday from the inaugural 2014 Palliative Care in Oncology Symposium explored how the use of "smart technology" and medical oncologist/palliative care specialist partnerships can successfully integrate palliative care into treatment and the impact of financial hardships on people living with cancer.
read press release 



C.D.C. Issues New Guidelines for Ebola Care

(New York Times) Oct 20, 2014 - The new protocols are based on procedures followed by the international aid group Doctors Without Borders.
read article 



Unanimous FDA Panel Support for Novartis' Secukinumab

(PharmaTimes [UK]) Oct 21, 2014 - Advisors to the US Food and Drug Administration have voted unanimously to support approval of Novartis’ secukinumab for moderate-to-severe plaque psoriasis.
read article 



AbbVie, Shire Terminate Year’s Biggest Deal

(Wall Street Journal) Oct 20, 2014 - AbbVie Inc. and Shire PLC officially agreed to terminate their $54 billion deal, killing the year’s biggest agreed-upon merger and giving a win to the Obama administration, which has fought overseas merger deals prompted by tax advantages.
read article (paid subscription required) 



Actavis Competing With Sanofi for Omega Pharma Deal

(Bloomberg) Oct 21, 2014 - Actavis Plc is among the bidders for Omega Pharma NV, people with knowledge of the matter said, as the U.S. drugmaker continues hunting for acquisitions.
read article 



Boehringer’s New Lung Drug to Cost $96,000 a Year

(Bloomberg) Oct 20, 2014 - Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG’s competing product.
read article 



BE ON THE LOOKOUT FOR… AMA RUC Survey of Subcutaneous, Intramuscular, and Intravenous Injection Codes

(ASCO in Action) Oct 20, 2014 - In the next few weeks, the American Society of Clinical Oncology (ASCO) in collaboration with multiple specialty societies will randomly distribute an American Medical Association (AMA) Relative Value Scale Update Committee (RUC) survey of the therapeutic injection CPT ® codes 96372, 96374, and 96375 the chemotherapy injection CPT ® codes 96401, 96409, and 96411.
read article 



Celgene Participates in New Round of Investment for Sequenta

(Sequenta) Oct 20, 2014 - Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced an equity investment by Celgene Corporation and other strategic investors.
read corporate press release 



Unum Therapeutics, A Cellular Immunotherapy Company, Launches with $12M

(Boston Globe) Oct 21, 2014 - Unum Therapeutics announced its launch Tuesday with $12 million in funding led by Fidelity Biosciences and Atlas Venture, with participation from Sanofi-Genzyme BioVentures.
read article (free registration required) 



Healthtech: Providence Cancer Spinoff Gets Anti-tumor Technology into Clinical Trial

(Portland Business Journal/Healthcare Inc. NW blog) Oct 20, 2014 - AgonOx, a Providence Cancer Center spinoff, has hit a new milestone, with a new cancer therapy clinical trial getting under way.
read article 



Optim Oncology Expands and Enhances Patient Care with the Addition of Two Locations

(McKesson) Oct 20, 2014 – Optim Oncology, a practice in The US Oncology Network and a leader in providing quality oncology care throughout the greater Oklahoma City area, announced today it has expanded its practice to include two additional locations, through the acquisition of Artesian Cancer Centers.
read corporate press release 



North Carolinian Credits Early Cancer Diagnosis To New Health Coverage

(Kaiser Health News/The Charlotte Observer) Oct 20, 2014 - Kimberly Tonyan illustrates what the law was designed to accomplish: Because she had insurance, she got care before her cancer advanced. While her care has been expensive, it headed off more costly procedures, such as chemotherapy and radiation.
read article 



At Home with the Specialist: Oncologists and Other Specialists Launching Patient-centered Medical Homes

(Modern Healthcare) Oct 18, 2014 - Solo practice endocrinologist Carol Greenlee is one of a small number of specialist physicians in the country who operate their practice as a patient-centered medical home, a model pioneered by primary-care doctors.
read article 



ACCC to Develop Comprehensive Program on Immuno-Oncology for Community-Based Providers

(ACCC) Oct 21, 2014 - The Association of Community Cancer Centers (ACCC) has been provided with a charitable contribution from Bristol-Myers Squibb to develop a comprehensive program in Immuno-Oncology for community-based providers.
read press release 



October 21, 2014: COA Releases 2014 Community Oncology Practice Impact Report

(COA) Oct 21, 2014 - Over the past 8 years, 313 cancer treatment facilities have closed and 544 community cancer practices have been acquired by or affiliated with hospitals. New to this year’s report, COA tracked that over the past 2 years 74.5% of the acquisitions/affiliations have been with hospitals receiving 340B drug discounts.
read article 



Oasmia Pharmaceutical AB: Oasmia's Lead Human Oncology Product Paclical Shows a Positive Risk/Benefit Profile Versus Standard Treatment in Pivotal Phase III Clinical Study

(NASDAQ) Oct 21, 2014. Oasmia Pharmaceutical AB (publ) today announced that the full clinical trial report of Paclical, for the treatment of epithelial ovarian cancer, shows a positive risk/benefit profile. The data will serve as the basis of a Marketing Authorisation Application to the European Medicines Agency (EMA), which the company intends to submit in early 2015.
read article 



Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

(CNNMoney) Oct 21, 2014 - Agios Pharmaceuticals, Inc. today announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation.
read article 



UCLA Scientists Discover Protein that Can Accelerate Cancer Patients’ Recovery After Radiation and Chemotherapy

(UCLA) Oct 20, 2014 - Scientists from UCLA’s Jonsson Comprehensive Cancer Center have shown for the first time how a unique protein found in human bone marrow can drive stem cells to repair our blood system after an injury.
read press release 



ACG: Recent Increase in Incidence of Young-onset CRC

(HCPLive.com/HealthDay News) Oct 20, 2014 - The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American College of Gastroenterology, held from Oct. 17 to 22 in Philadelphia.
read article 



Genetic Test Showing Increased CRC Risk Prompts No Action

(Medscape Medical News) Oct 21, 2014 - Genetic testing designed to determine the risk of developing colorectal cancer (CRC) failed to prompt people to sign up for CRC screening, even when the test showed an elevated risk of colon cancer, according to a study published online October 20 in the Annals of Internal Medicine.
read article (free registration required) 



Image Guided Radiation Therapy is Commonly Used to Ensure Accuracy in Treating Pediatric Tumors

(ASTRO) Oct 17, 2014 - Image guided radiation therapy (IGRT) is a commonly used modality to ensure treatment accuracy in the management of pediatric tumors; however, consensus recommendations are needed in order to guide clinical decisions on the use of IGRT in treating pediatric patients, according to a new study.
read press release 



Biological Clock Disruptions Increase Breast Cancer Risk, UGA Study Finds

(UGA Today/University of Georgia) Oct 17, 2014 - The disruption of a person's circadian rhythm—their 24-hour biological clock—has been linked to an increased risk of breast cancer, according to new University of Georgia research.
read article 



New Proposal for Combined Therapy Proves Effective Against a Notoriously Resistant HER2+ Breast Cancer Subtype

(VHIO [Barcelona, Spain]) Oct 13, 2014 - Research has shown the combined strategy of chemotherapy plus trastuzumab (a selective therapy against HER2 receptors), as effective in reducing tumors of a specific HER2+ breast cancer subtype known as p95HER2.
read press release 



Patients Treated with Radiation Therapy Who Have Tumors in Left Breast Have Comparable Overall Survival to Those with Tumors in the Right Breast

(ASTRO) Oct 20, 2014 - Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a new study.
read press release 



Boehringer Ingelheim Initiates Global Phase III Study Investigating Nintedanib* in Patients with Colorectal Cancer Refractory to Standard Treatments

(Boehringer Ingelheim) Oct 21, 2014 - Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer (CRC).
read corporate press release